Volume 27, Issue 3 (May 2025) 27, 342–354; 10.4103/aja202492
Medical treatment prior to micro-TESE
Dasgupta, Sujoy1,2; Le, Thanh Sang2,3; Rambhatla, Amarnath2,4; Shah, Rupin2,5; Agarwal, Ashok2
1Department of Reproductive Medicine, Genome Fertility Centre, Kolkata 700025, West Bengal, India 2Global Andrology Forum, Moreland Hills, OH 44022, USA 3Department of Andrology, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam 4Henry Ford Hospital Vattikuti Urology Institute, Urology, Detroit, MI 48075, USA 5Department of Urology, Lilavati Hospital and Research Centre, Mumbai 400050, Maharashtra, India
Correspondence: Dr. S Dasgupta (dr.sujoydasgupta@gmail.com)
Originally published: December 24, 2024 Received: March 22, 2024 Accepted: October 13, 2024
Abstract |
Except in cases of hypogonadotropic hypogonadism, the use of medical therapy before microsurgical testicular sperm extraction (micro-TESE) is controversial. In some studies, hormone therapy has been shown to improve the possibility of sperm retrieval during micro-TESE and even lead to the presence of sperm in the ejaculate in some cases, thereby obviating the need for micro-TESE. However, their routine use before micro-TESE in cases of nonobstructive azoospermia (NOA) being associated with hypergonadotropic hypogonadism and eugonadism (normogonadotropic condition) has not been supported with robust evidence. In this review, we discuss different types of medical therapy used before micro-TESE for NOA, their risks and benefits, and the available evidence surrounding their use in this setting. Keywords: aromatase inhibitors; gonadotropins; male infertility; microsurgical testicular sperm extraction; nonobstructive azoospermia; selective estrogen receptor modulators; successful sperm retrieval
Full Text |
PDF |
|
|
Browse: 33 |
|